AbbVie is in advanced discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion. Should this transaction be successfully concluded, it will bolster AbbVie's product portfolio following the expiration of the patent for its flagship drug Humira. Statistics reveal that since 2023, AbbVie has invested over $20 billion in mergers and acquisitions.